Table 1.

Results of primary and secondary endpoints

	Baseline visit week 0	Intermediate visit week 4	End visit week 8	Difference baseline–end	Significance baseline–end
PASI
Tacalcitol	8.53	6.53	5	−3.53	P < 0.0001
Tacalcitol + Oravex	9.6	5.4	2.8	−6.8
NAPSI
Tacalcitol	0.38	0.43	0.38	0	P = 0.0480
Tacalcitol + Oravex	2.91	2.45	1.68	−1.23
DLQI
Tacalcitol	5.67	3.67	2.64	−3.03	P = 0.0056
Tacalcitol + Oravex	8.53	2.63	1.86	−6.67
Scalp lesion
Tacalcitol	0.6	0.53	0.6	0	P = 0.0038
Tacalcitol + Oravex	0.87	0.8	0.27	−0.6
Pruritus
Tacalcitol	66.7%	40.0%	26.7%	−40%
Tacalcitol + Oravex	80.0%	6.7%	0%	−80%	P < 0.0001
Lesion of target plaque
Erythema
Tacalcitol	2.20	1.80	1.47	−0.73	P = 0.0080
Tacalcitol + Oravex	2.93	1.80	1.13	−1.80
Infiltration
Tacalcitol	1.53	0.93	0.53	−1.0	P = 0.0011
Tacalcitol + Oravex	2.47	1.13	0.47	−2.0
Scaling
Tacalcitol	1.60	0.87	0.20	−1.40	P = 0.0291
Tacalcitol + Oravex	2.27	1.00	0.13	−2.14